Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients

Hadeel Delman Najim; Mohammed Mahmood Mohammed; Abbas Mahdi Rahmah

doi:10.31351/vol33iss3pp142-149

Article Details

Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients

Authors:

Hadeel Delman Najim | Mohammed Mahmood Mohammed | Abbas Mahdi Rahmah

Publisher:

University of Baghdad

Journal:

Iraqi Journal of Pharmaceutical Sciences Vol.33 Issue 3, pp.142-149

Document Type:

Article

Publication Date:

9/2024

Document Language:

English

Document ID (Org No.):

2001363233

pISSN:

2521-3512

DOI:

10.31351/vol33iss3pp142-149

Keywords:

Abstract:

 To evaluate the efficacy of empagliflozin on the quality of life (QoL) and glycemic index in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional oral anti-diabetic agents (OADs).
A pre-post study involved forty T2DM patients who were on a combination of three OADs (glimepiride + metformin + vildagliptin) with glycated hemoglobin A1c (HbA1c) 7.0% - 12.0%. All patients received empagliflozin (10 mg/day) as add-on therapy for 16 weeks.
Adding empagliflozin showed significant reduction in postprandial plasma glucose (PPG), (HbA1c), body mass index (BMI) and index of central obesity (ICO) (p<0.001). Significant improvements have been shown in the Quality of Life in Iraqi type 2 diabetic patients (QOLSID) scores post-intervention (p<0.001). Besides, good QoL was reported in patients with lower BMI and among those who had DM for duration less than 10 years.
The outcome of this study showed that empagliflozin as add-on to oral antidiabetic triple therapy in poorly controlled T2DM has achieved a better weight management, well glycaemic control and enhanced QoL through the therapy, and was well tolerated among the study sample.
Keywords: Empagliflozin, Glycemic index, Quality of life, SGLT2 inhibitors, Type 2 DM.

Article Details

Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients

Authors:

Hadeel Delman Najim | Mohammed Mahmood Mohammed | Abbas Mahdi Rahmah

Publisher:

University of Baghdad

Journal:

Iraqi Journal of Pharmaceutical Sciences Vol.33 Issue 3, pp.142-149

Document Type:

Article

Publication Date:

9/2024

Document Language:

English

Document ID (Org No.):

2001363233

pISSN:

2521-3512

DOI:

10.31351/vol33iss3pp142-149

type 2 DM

empagliflozin

hemoglobin A1c

quality of life

Issues

Article Details

Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients

Authors: Hadeel Delman Najim | Mohammed Mahmood Mohammed | Abbas Mahdi Rahmah

Publisher: University of Baghdad

Journal: Iraqi Journal of Pharmaceutical Sciences Vol.33 Issue 3, pp.142-149

Document Type: Article

Publication Date: 9/2024

Document Language: English

Document ID (Org No.): 2001363233

pISSN: 2521-3512

DOI: 10.31351/vol33iss3pp142-149

type 2 DM

empagliflozin

hemoglobin A1c

quality of life

Issues

Authors:

Hadeel Delman Najim | Mohammed Mahmood Mohammed | Abbas Mahdi Rahmah

Publisher:

University of Baghdad

Journal:

Iraqi Journal of Pharmaceutical Sciences Vol.33 Issue 3, pp.142-149

Document Type:

Article

Publication Date:

9/2024

Document Language:

English

Document ID (Org No.):

2001363233

pISSN:

2521-3512

DOI:

10.31351/vol33iss3pp142-149